Cannabinoids

Since its founding, Linnea has focused on developing top-tier plant-based Active Pharmaceutical Ingredients at its GMP-certified facility in Switzerland. Known for its dedication to excellence, we ensure that every ingredient adheres to rigorous standards. From 2014 the company has expanded its focus to cannabinoid research and development, launching its first full-pharma grade cannabinoid ingredient in 2016. This marked the beginning of our commitment to applying the same science-based, uncompromising approach to the manufacturing of cannabinoids from natural Cannabis sativa L. Looking ahead, Linnea is poised to reinforce its operations with a new state-of-the-art manufacturing plant dedicated exclusively to medical cannabis derivatives. This makes the company one of the very few industry leaders devoted to the highest levels of quality, driving sustained growth and cutting-edge advancements in the cannabinoid space. As an additional recognition on this aspect, Linnea collaborated with EDQM on the preparation of the CBD and cannabis flowers Ph.Eur. monographs (published in 2024) and is collaborating on the current writing of the Cannabis extracts Ph.Eur. monograph. We can provide: -pharma-grade 5% cannabidiol (CBD) and 5% cannabigerol (CBG) standardized in MCT oil as well as combinations (2.5% - 5% / 1:1 - 2:1 - 1:2) - DMF is available -CBD isolate with a purity grade 98-102%, with DMF, CEP on-going, Ph.Eur. compliant We guarantee full traceability of raw materials, grown in European plantations from certified seeds (EU database)